Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO), the kings of the titanic weight-loss drugs market, might have a problem on their hands. After reporting their third-quarter earnings, shares of both ...
The latest celebrity weight-loss drug to be given the nod in Hong Kong will be available in December, but experts cautioned ...
Viking aims to compete against market giants Eli Lilly and Novo Nordisk in the billion-dollar weight loss drug market. The ...
Critics, including Senator Bernie Sanders, question whether the push to block alternatives is truly about safety — or simply ...
1d
AstraZeneca and Viking Therapeutics both presented encouraging data on their obesity pills. Meanwhile, here’s how Americans ...
A Novo Nordisk trial also discovered an association between Wegovy prescriptions and fewer hospitalizations for any cause. In the study, 33.4% of patients taking Wegovy were admitted, compared to ...
Excitement is building around a new weight loss drug, CagriSema, which is expected to surpass the effects of popular drugs ...
Novo Nordisk reported earnings, posting some chunky year-over-year growth and far outperforming its only real rival at the ...
Novo Nordisk, the maker of Ozempic ... An oral form of semaglutide approved for improving blood sugar control in adults with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback